New trends in the science of botulinum toxin-A as applied in dystonia

International Journal of Neuroscience

Volumn 121, Issue SUPPL. 1, 2011, Pages 22-34

  Pickett, Andy ^a   Rosales, Raymond L ^b,c  

^a IPSEN   (France)

^b UNIVERSITY OF SANTO TOMAS   (Philippines)

^c Metropolitan Medical Center Manila   (Philippines)

Author keywords

Botulinum toxin; diffusion; dystonia; pharmacology

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ARTICLE; DRUG DIFFUSION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DYSTONIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; NEUROSCIENCE; TREATMENT RESPONSE;

BOTULINUM TOXINS, TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSTONIC DISORDERS; HUMANS; NEUROMUSCULAR AGENTS;

EID: 79952299441     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2010.539306     Document Type: Article

References (106)

1. Abbruzzese, G., & Berardelli, A. (2006). Neurophysiological effects of botulinum toxin type A. Neurotoxicity Research, 9, 109-114.
2. Alpiner, N. (2009). Botulinum toxin injections using computerised tomography guidance for enhanced anatomical localization. Presented at 70th Annual Assembly of the American Academy of Physical Medicine and Rehabilitation, 22-26 October, 2009, Austin, TX, USA, Poster 303.
3. Aoki, R. (1999). Preclinical update on BotoxR® (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations. European Journal of Neurology, 6(Suppl 4), S3-S10.
4. Aoki, R., Merlino, G., Spanoyannis, A., & Wheeler, L. (1999). BotoxR® (botulinum toxin type A) purified neurotoxin complex prepared from the new bulk toxin retains the same preclinical efficacy as the original but with reduced immunogenicity. Neurology, 52(Suppl 2), A521-A522.
5. Arnon, S. S., Schechter, R., Inglesby, T. V., Henderson, D. A., Eitzen, E., Fine, A. D., et al. (2001). Botulinum toxin as a biological weapon: Medical and public health management. JAMA, 285 (8), 1059-1070. (Pubitemid 32176420)
6. Atassi, Z. (2006). On the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology, 152, 1891-1895.
7. Barbano, R. L. (2001). Needle EMG is useful. Muscle & Nerve, 24(11), 1567-1568.
8. Benecke, R., Jost, W. H., Kanovsky, P., Ruzicka, E., Comes, G., & Grafe, S. (2005). A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology, 64(1949-1951).
9. Bentivoglio, A. R., Fasano, A., Ialongo, T., Soleti, F., Lo-Fermo, S, & Albanese, A. (2009a). Fifteen-year experience in treating blepharospasm with Botox or Dysport: Same toxin, two drugs. Neurotoxicity Research, 15(3), 224-231.
10. Bentivoglio, A. R., Fasano, A., Ialongo, T., Soleti, F., Lo-Fermo, S, & Albanese, A. (2009b). Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm. European Journal of Neurology, 16(3), 392-398.
11. Berardelli, A. (1999). Transcranial magnetic stimulation in movement disorders. Electroencephalography Clinical Neurophysiology, 51(Suppl.1), 276-280.
12. Berardelli, A., Rothwell, J. C., Day, B. L., & Marsden, C. D. (1985). Pathophysiology of blepharospasm and oromandibular dystonia. Brain, 108(3), 593-608. (Pubitemid 15021560)
13. Borodic, G. E., Cozzolino, D., & Ferrante, R. (1991). Innervation zone of orbicularis oculi muscle and implications for botulinum A toxin therapy. Opthalmic Plastic and Reconstructive Surgery, 7(1), 54-60.
14. Borodic, G., Johnson, E., Goodnough, M., & Schantz, E. (1996). Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology, 46, 26-29. (Pubitemid 26178103)
15. Depedibi, R., Unlu, E., Cevikol, A., Akkaya, T., Cakci, A., Cerekci, R., et al. (2008). Ultrasound-guided botulinum toxin type A injection to the iliopsoas muscle in the management of children with cerebral palsy. Neurorehabilitation, 23(3), 199-205. (Pubitemid 352039966)
16. Deshpande, S., Gormley, M. E., & Carey, J. R. (2006). Muscle fiber orientation in muscles commonly injected with botulinum toxin: An anatomical pilot study. Neurotoxicity Research, 9(2,3), 115-120.
17. Dolimbek, B. Z., Aoki, K. R., Steward, L. E., Jankovic, J., & Atassi, M. Z. (2007). Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Molecular Immunology, 44, 1029-1041. (Pubitemid 44414991)
18. Dong, M., Liu, H., Tepp, W., Johnson, E. A., Janz, R., & Chapman, E. R. (2008). Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Molecular Biology of the Cell, 19, 5226-5237.
19. Dressler, D. (2004). Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Movement Disorders, 19(Suppl 8), S92-S100.
20. Dressler, D. (2009). Routine use of XeominR® in patients previously treated with BotoxR®: Long term results. European Journal of Neurology, 16(Suppl 2), 2-5.
21. Eekhof, J., Aramideh, M., Bour, L., Hilgevoord, A., Speelman, H., & Ongerboer de Visser, B. (1996). Blink reflex recovery curves in blepharospasm, torticollis spasmodica, and hemifacial spasm. Muscle & Nerve, 19, 10-15. (Pubitemid 26010945)
22. Eisele, K-H., & Taylor, H-V. (2008). Dissociation of the 900kDa neurotoxin complex from C. botulinum under physiological conditions. Toxicon, 51, 10.
23. Farmer, S. F., Sheean, G. L., Mayston, M. J., Rothwell, J. C., Marsden, C. D., Conway, B. A., et al. (1998). Abnormal motor unit synchronization of antagonist muscles underlies pathological cocontraction in upper limb dystonia. Brain, 121(5), 801-814. (Pubitemid 28220890)
24. Frevert, J. (2009). XeominR®: An innovative new botulinum toxin type A. European Journal of Neurology, 16(Suppl. 2), 11-13.
25. Friday, D., Bigalke, H., & Frevert, J. (2002). In vitro stability of botulinum toxin complex preparations at physiological pH and temperature. Naunyn-Schmiedebergs Archives of Pharmacology, 365(Suppl 2), R20.
26. Fu, F-N., Sharma, S. K., & Singh, B. R. (1998). A protease-resistant novel hemagglutinin purified from type A Clostridium botulinum. Journal of Protein Chemistry, 7(1), 53-60. (Pubitemid 28086476)
27. Fujinaga, Y. (2010). Interaction of botulinum toxin with the epithelial barrier. Journal of Biomedicine & Biotechnology, doi: 10.1155/2010/974943.
28. Gelb, D. J., Yoshimura, D. M., Olney, R. K., Lowenstein, D. H., & Aminoff, M. J. (1991). Change in the pattern of muscle activity following botulinum toxin injections for torticollis. Annals of Neurology, 29, 370-376.
29. Giladi, N. (1997). The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. Journal of Neurological Sciences, 152, 132-135.
30. Goodmurphy, C. W. (1996). A comparative morphological study of two human facial muscles: The orbicularis oculi and the corrugator supercilii. Masters thesis, University of British Columbia, August 1996.
31. Goodmurphy, C. W., & Ovalle, W. K. (1999). Morphological study of two human facial muscles: Orbicularis oculi and corrugator supercilii. Clinical Anatomy, 12, 1-11. (Pubitemid 29016822)
32. Grünewald, R., Yoneda, Y., Shipman, J., & Sagar, H. (1997). Idiopathic focal dystonia: A disorder of muscle spindle afferent processing? Brain, 120, 2179-2185.
33. Hadfield, A. T., Petsko, G., Lindo, P., & Singh, B. R. (1999). Preliminary crystallographic studies of a protease-resistant botulinum neurotoxin associated protein Hn-33. Acta Crystallographica, D55, 1537-1539.
34. Hambleton, P., Pickett, A. M., & Shone, C. C. (2007). Botulinum toxin: From menace to medicine. In A. B. Ward & M. P. Barnes (eds.), Clinical Uses of Botulinum Toxins., Cambridge, Cambridge University Press.
35. Happak, W., Liu, J., Burggasser, G., Flowers, A., Gruber, H., & Freilinger, G. (1997). Human facial muscles: Dimensions, motor endplate distribution, and presence of muscle fibers with multiple motor endplates. Anatomical Record, 249, 276-284. (Pubitemid 27426332)
36. Hunt, T., & Clarke, K. (2009). Potency evaluation of a formulated drug product containing 15-kD botulinum neurotoxin type A. Clinical Neuropharmacology, 32(1), 28-31.
37. Jackson, M. B., & Chapman, E. R. (2008). The fusion pores of Ca2+-triggered exocytosis. Nature Structural & Molecular Biology, 15(7), 684-689.
38. Jankovic, J. (2001). Needle EMG is rarely required. Muscle & Nerve, 24(11), 1568-1570.
39. Jones, S. J., Sheean, G., Ceballos-Baumann, A. O., & Marsden, C. D. (1995). Evidence for enhanced sensorimotor cortex excitability in dystonia (abstract). Electroencephalography and Clinical Neurophysiology, 94(Suppl. 1), S233.
40. Jost, W. H., Blumel, J., &Grafe, S. (2007). Botulinum neurotoxin type A free of complexing proteins (XEOMINR®) in focal dystonia. Drugs, 67(5), 669-683.
41. Kaji, R., Rothwell, J. C., Katayama, M., Ikeda, T., Kubori, T., Kohara, N., et al. (1995). Tonic vibration reflex andmuscle afferent block in writer's cramp. Annals of Neurology, 38(2), 155-162.
42. Kaňovský, P., Streitová, H., Dufek, J., & Rektor, I. (1997). Lateralization of the P22/N30 component of the median nerve in patients with cervical dystonia. Movement Disorders, 12, 553-560. (Pubitemid 27322885)
43. Kaňovský, P., Streitová, H., Dufek, J., Znojil, V., Daniel, P., & Rektor, I. (1999). Lateralization of the P22/N30 precentral cortical component of the median nerve somatosensory evoked potentials is different in patients with a tonic or tremulous form of cervical dystonia. Movement Disorders, 14, 642-651. (Pubitemid 30011458)
44. Karsai, S, & Raulin, C. (2007). Do different formulations of botulinum toxin type A really have different migration characteristics? Journal of Cosmetic Dermatology, 7(3), 230.
45. Kim, D., Oh, B., & Paik, N. (2006). Central effect of botulinum toxin type A in humans. International Journal of Neuroscience, 116, 667-680. (Pubitemid 43879706)
46. Kukreja, R., Chang, T-W., Cai, S., Lindo, P., Riding, S., Zhou, Y., et al. (2009). Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins. Toxicon, 53, 616-624.
47. Lamanna, C. (1959). The most poisonous poison. Science, 130, 763-772.
48. Lange, O., Bigalke, H., Dengler, R., Wegner, F., deGroot, M., & Wohlfarth, K. (2009). Neutralising antibodies and secondary therapy failure after treatment with botulinum toxin type A: Much ado about nothing? Clinical Neuropharmacology, 32(4), 213-218.
49. Lawrence, I., & Moy, R. (2009). An evaluation of neutralizing antibody induction during treatment of glabellar lines with a new US formulation of botulinum neurotoxin type A. Aesthetic Surgery Journal, 29(Suppl 6S), S66-S71.
50. Lee, J. C., Yokata, K., Arimitsu, H., Hwang, H-J., Sakaguchi, Y., Cui, J., et al. (2005). Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology, 113, 301-312.
51. Lee, L. V., Maranon, E., Demaisip, C., Paralta, O., Borres-Icasiano, R., Arancillo, J., et al. (2002). The natural history of sex-linked recessive dystonia parkinsonism of Panay, Philippines (XDP). Parkinsonism & Related Disorders, 9(1), 29-38. (Pubitemid 36177217)
52. Lim, E. C. H., Quek, A. M. L., & Seet, R. C. S. (2006). Botulinum toxin-A injections via electrical motor point stimulation to treat writer's cramp: Pilot study. Neurology, Neurophysiology, and Neuroscience, 4, 1-7.
53. Lukban, M. B., Rosales, R. L., & Dressler, D. (2009). Effectiveness of botulinum toxin-A for upper and lower limb spasticity in children with Cerebral Palsy: A summary of evidence. Journal of Neural Transmission, 166, 319-331.
54. Manganotti, P., Acler, M., Formaggio, E., et al. (2010). Changes in cerebral activity after decreased upper-limb hypertonus: An EMG-fMRI study. Magnetic Resonance Imaging, 28(5), 646-652.
55. Mander, G., Fink, K., & Vey, M. (2009). Experimental conditions substantially influence botulinum toxin potency testing. Clinical Neuropharmacology, 32(4), 234.
56. Mink, J. W. (1996). The basal ganglia: Focused selection and inhibition of competing motor programs. Progress in Neurobiology, 50, 381-425.
57. Mohammadi, B., Buhr, N., Bigalke, H., Dengler, R., & Kollewe, K. (2009). A long-term follow-up of botulinum toxin A in cervical dystonia. Neurological Research, 31(5), 463-466.
58. Molloy, F. M., Shill, H. A., Kaelin-Lang, A., & Karp, B. I. (2002). Accuracy of muscle localization without EMG: Implications for treatment of limb dystonia. Neurology, 58(5), 805-807. (Pubitemid 34211562)
59. Murase. N., Kaji, R., Shimazu, H., et al. (2000). Abnormal premovement gating of somatosensory input in writer's cramp. Brain, 123(9), 1813-1829. (Pubitemid 30664284)
60. Nakashima, K., Rothwell, J. C., Day, B. L., Thompson, P. D., Shannon, K., & Marsden, C. D. (1989). Reciprocal inhibition between forearm muscles in patients with writer's cramp and other occupational cramps, symptomatic hemidystonia and hemiparesis due to stroke. Brain, 112, 681-697.
61. National Institutes of Health (NIH) Consensus Development Program. (1990). Clinical Use of Botulinum Toxin. NIH Consensus Development Conference Statement, November 12-14, 1990. Accessed as http://consensus.nih.gov/1990/ 1990BotulinumToxin083html.htm, 20 April 2010.
62. Naumann, M., & Jankovic, J. (2004). Safety of botulinum toxin type A: A systematic review and meta-analysis. Current Medical Research and Opinion, 20(7), 981-990. (Pubitemid 38954460)
63. Naumann, M., & Reiners, K. (1997). Long-latency reflexes of hand muscles in idiopathic focal dystonia and their modification by botulinum toxin. Brain, 120, 409-416. (Pubitemid 27153634)
64. Naumann, M., Abu-Shakra, S., Boodhoo, T., Miller-Messana, M. A., Demos, G., & Brin, M. F. (2009). A meta-analysis of neutralizing antibody conversion following a specific formulation of botulinum toxin type A (BoNTA, Allergan, Inc.). Movement Disorders, 24(Suppl 1), We-156.
65. Naumann, M., Yakovleff, A., & Durif, F. (2002). A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. Journal of Neurology, 249(1), 57-63. (Pubitemid 34119024)
66. Panizza, M., Lelli, S., Nilsson, J., et al. (1990). H-reflex recovery curve and reciprocal inhibition of H-reflex in different kinds of dystonia. Neurology, 40, 824-828. (Pubitemid 20159622)
67. Panjwani, N., O'Keeffe, R., & Pickett, A. (2008). Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. The Botulinum Journal, 1(1), 156-166.
68. Pauri, F., Boffa, L., Cassetta, F., Pasqualetti, P., & Rossini, P. M. (2000). Botulinum toxin type-A treatment in spastic paraparesis: A neurophysiological study. Journal of Neurological Sciences, 181, 89-97.
69. Pickett, A. (2009). DysportR®: Pharmacological properties and factors that influence toxin action. Toxicon, 54(5), 683-689.
70. Pickett, A., & Caird, D. (2008). Comparison of type A botulinum toxin products in clinical use. Journal of Clinical Pharmacy and Therapeutics, 33, 327-328. (Pubitemid 351629749)
71. Pickett, A., & Perrow, K. (2010). Formulation composition of botulinum toxins in clinical use. Journal of Drugs in Dermatology, 9(9), 1085-1091.
72. Pickett, A., Dodd, S., & Rzany, B. (2008). Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications. Journal of Cosmetic and Laser Therapy, 10, 181-183.
73. Poulain, B., Popoff, M. R., & Molgo, J. (2008). How do the botulinum neurotoxins block neurotransmitter release: From botulism to the molecular mechanism of action. The Botulinum Journal, 1(1), 14-87.
74. Priori, A., Berardelli, A., Mercuri, B., & Manfredi, M. (1995). Physiological effects produced by botulinum toxin treatment of upper limb dystonia. Changes in reciprocal inhibition between forearm muscles. Brain, 118, 801-807.
75. Quartarone, A., Rizzo, V., Terranova, C., Morgante, F., Schneider, S., Ibrahim, N., et al. (2009). Abnormal sensorimotor plasticity in organic but not in psychogenic dystonia. Brain, 132(10), 2871-2877.
76. Racette, B. A., McGee-Minnich, L., & Perlmutter, J. S. (1999). Efficacy and safety of a new bulk toxin of botulinum toxin in cervical dystonia: A blinded evaluation. Clinical Neuropharmacology, 22(6), 337-339.
77. Rao, S., Starr, R. L., Morris, M. G., & Lin, W-J. (2007). Variations in expression and release of botulinum neurotoxin in Clostridium botulinum type A strains. Foodborne Pathogens and Disease, 4(2), 201-207. (Pubitemid 47041359)
78. Reilly, J. A., Hallet, M., Cohen, L. G., Tarkka, I., & Dang, N. (1992). The N30 component of somatosensory evoked potentials in patients with dystonia. Electroencephalography and Clinical Neurophysiology, 84, 243-247.
79. Ridding, M., Sheean, G., Rothwell, J. C., Inzelberg, R., & Kujirai, T. (1995). Changes in the balance between motor cortical excitation and inhibition in focal, task-specific dystonia. Journal of Neurology, Neurosurgery and Psychiatry, 59, 493-498.
80. Roggenkamper, P., Jost, W. H., Bihari, K., Comes, G., & Grafe, S. (2006). Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. Journal of Neural Transmission, 113, 303-312. (Pubitemid 43201097)
81. Rona, S., Berardelli, A., Vacca, L., Inghilleri, M., & Manfredi, M. (1998). Alterations of motor cortical inhibition in patients with dystonia. Movement Disorders, 13, 118-124. (Pubitemid 28029862)
82. Rosales, R. L., & Chua-Yap, A. (2008). Evidence-based systematic review on the efficacy and safety of botulinum toxin therapy in post-stroke spasticity. Journal of Neural Transmission, 115(4), 617-623.
83. Rosales, R. L., & Dressler, D. (2010). On muscle spindles, dystonia and botulinum toxin. European Journal of Neurology, 17(Suppl. 1), 71-80.
84. Rosales, R. L., Arimura, K., Gamez, G., & Osame, M. (1995). X-linked dystonia-parkinsonism: Botulinum toxin therapy and stimulation single-fiber electromyography. Electroencephelography and Clinical Neurophysiology (Section of Electromyography and Motor Control), 97(Suppl.), S234-S235.
85. Rosales, R. L., Arimura, K., Takenaga, S., & Osame, M. (1996). Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle & Nerve, 19, 488-496.
86. Rosales, R. L., Bigalke, H., & Dressler, D. (2006). Pharmacology of botulinum toxin: differences between type A preparations. European Journal of Neurology, 13(Suppl. 1), 2-10.
87. Rosales, R. L., Delgado, M. S., & Rosales, M. E. (2002). Spasticity, Xlinked dystonia, parkinsonism and botulinum toxin A: The local scenario. Proceedings of the 3rd World Congress of Neurological Rehabilitation, Battistin, Dam, Tonin (eds), Monduzzi Editore, pp. 121-126.
88. Rosales, R. L., Delgado, M., & Malicdan, M. (2004). Botulinum toxin A and muscle afferent block in X-linked dystonia-parkinsonism of Panay. Movement Disorders, 19(Suppl 9), S103-S104.
89. Sakaguchi, G. (1983). Clostridium botulinum toxins. Pharmacy And Therapeutics, 19, 165-194.
90. Scott, A. (1985). Botulinum toxin treatment of strabismus. American Orthodontics Journal, 35, 28-29.
91. Scott, A. B. (1981). Botulinum toxin injection of the eye muscles to correct strabismus. Transactions of the American Opthalmological Society, 79, 734-770.
92. Scott, A. B. (2004). Development of botulinum toxin therapy. Dermatologic Clinics, 22, 131-133.
93. Scott, A. B., Rosenbaum, A., & Collins, C. C. (1973). Pharmacologic weakening of extraocular muscles. Investigative Ophthalmology, 12, 924-927.
94. Senkarova, Z., Hlustik, P., Otruba, P., Herzig, R., & Kanovsky, P. (2009). Modulation of cortical activity in patients suffering from upper arm spasticity following stroke and treated with botulinum toxin A: An fMRI study. Journal of Neuroimaging, 20(1), 9-15.
95. Smith, T. J., Hill, K. K., Foley, B. T., Detter, J. C., Munk, A. C., Bruce, D. C., et al. (2007). Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains; BoNT/A3, /Ba4 and /B1 clusters located within plasmids. PloS One, 12:e1271.
96. Sohn, Y. H., & Hallett, M. (2004). Disturbed surround inhibition in focal hand dystonia. Annals of Neurology, 56, 595-599. (Pubitemid 39319356)
97. Stinear, C. M., & Byblow, W. D. (2004). Impaired modulation of intracortical inhibition in focal hand dystonia. Cerebral Cortex, 14 555-561. (Pubitemid 38579656)
98. Sugawara, Y., Matsumura, T., Takegahara, Y., Jin, Y., Tsukasaki, Y., Takeichi, M., et al. (2010). Botulinum haemagglutinin disrupts the intercellular epithelial barrier by directly binding E-cadherin. Journal of Cell Biology, 189(4), 691-700.
99. 18 FDG PET/CT in idiopathic cervical dystonia. Journal of Nuclear Medicine, 48(11), 1790-1795.
100. Tinazzi, M., Frasson, E., Polo, A., Tezzon, F., Bovi, P., Deotto, L., et al. (1999). Evidence for an abnormal cortical sensory processing in dystonia: Selective enhancement of lower limb P37/N50 somatosensory evoked potential. Movement Disorders, 14(3), 473-480. (Pubitemid 30011659)
101. Trompetto, C., Curra, A., Buccolieri, A., Suppa, A., Abbruzzese, G., & Berardelli, A. (2006). Botulinum toxin changes intrafusal feedback in dystonia: A study with the tonic vibration reflex. Movement Disorders, 21, 777-782. (Pubitemid 44028296)
102. Valls-Sole, J., Tolosa, E. S., & Riber, G. (1991). Neurophysiological observations on the effects of botulinum toxin treatment in patients with dystonic blepharospasm. Journal of Neurology, Neurosurgery and Psychiatry, 54, 310-313.
103. Wagman, J., & Bateman, J. B. (1953). Botulinum type A toxin: Properties of a toxic dissociation product. Archives of Biochemistry and Biophysics, 45, 375-383.
104. Walsh, R., & Hutchinson, M. (2007). Molding the sensory cortex: Spatial acuity improves after botulinum toxin treatment for cervical dystonia. Movement Disorders, 22, 2443-2446. (Pubitemid 351155995)
105. Ward, A. B., & Barnes, M. P. eds. (2007). Clinical Uses of Botulinum Toxins. Cambridge, Cambridge University Press.
106. Wenzel, R. G. (2004). Pharmacology of botulinum neurotoxin serotype A. American Journal of Health System Pharmacy, 61(Suppl. 6), S5-S10.